Identifying the Optimal Fractionation Schedules for Improved Response Rates and Survival in Patients with Metastatic Melanoma Treated with Ipilimumab and Radiotherapy

Author(s): Jason Liu, Cong Xu, Junjia Zhu, Jeffrey Sivik, Joseph J. Drabick, Heath B. Mackley*

Journal Name: Current Cancer Therapy Reviews

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Objective: There is a growing body of evidence that combining ipilimumab with higher doses of radiotherapy may improve the response rates and survival in patients with metastatic melanoma compared to lower doses of radiotherapy. However, the dose cutoff at which improved outcomes are more likely to occur has not been properly identified.

Methods: We conducted a retrospective analysis of 100 patients treated with ipilimumab and radiotherapy for metastatic melanoma at a single institution from May 2011 to January 2017. Demographic, clinical, and treatment factors, including the biological equivalent dose (BED) with an α/β of 7, were recorded. Endpoints of interest included infield and global complete response (CR) after the completion of radiation and ipilimumab based on the RECIST criteria (v1.1) and 12-month overall survival (OS).

Results: The BED cutoffs at which improved outcomes are more likely to occur are 46.5 Gy for infield CR, 50.9 Gy for global CR, and 46.5 Gy for 12 month OS. The least aggressive fractionation schedules used in this patient population that have a BED above the threshold for all 3 outcomes include 40 Gy in 20 fractions, 30 Gy in 6 fractions, and 24 Gy in 3 fractions.

Conclusion: This hypothesis-generating study suggests that patients who cannot receive ablative intent radiotherapy may be more likely to benefit from concurrent radiotherapy with ipilimumab if their fractionation schedule has a BED above 46.5 - 50.9 Gy. Prospective trials evaluating this question should be considered.

Keywords: Radioimmunotherapy, melanoma, ipilimumab, CTLA-4, radiotherapy, biological equivalent dose, dose cutoff.

[1]
Ferri F. Ferri’s clinical adviser. 2nd ed. Elsevier- Health Sciences Division: Philadelphia, USA 2017; pp. 773-5.
[2]
Gangadhar TC, Fecher LA, Miller CJ, et al. Melanoma. Abeloff’s Clin Oncol 2014; 1071-91. e3.
[3]
Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006; 355(1): 51-65.
[4]
Chandra RA, Wilhite TJ, Balboni TA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 2015; 4(11) e1046028
[5]
Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014; 3 e28780
[6]
Barker CA, Postow MA, Khan SA, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 2013; 1(2): 92-8.
[7]
Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013; 2(6): 899-906.
[8]
Theurich S, Rothschild SI, Hoffmann M, et al. Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol Res 2016; 2997: 1-12.
[9]
Hiniker SM, Reddy SA, Maecker HT, Swetter SM, Shura L, Knox SJ. A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. Radiat Oncol Biol 2015; 93(3): 578-88.
[10]
Koller KM, Mackley HB, Liu J, et al. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol Ther 2016; 18(1): 36-42.
[11]
Hammerich L, Bhardwaj N, Kohrt HE, Brody JD. In situ vaccination for the treatment of cancer. Immunotherapy 2016; 8(3): 315-30.
[12]
Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HEK. In situ tumor vaccination: Bringing the fight to the tumor. Hum Vaccines Immunother 2015; 11(8): 1901-9.
[13]
Derer A, Deloch L, Rubner Y, Fietkau R, Frey B, Gaipl US. Radio-immunotherapy-induced immunogenic cancer cells as basis for induction of systemic anti-tumor immune responses-pre-clinical evidence and ongoing clinical applications. Front Immunol 2015; 6: 505.
[14]
Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 2015; 33(51): 7415-22.
[15]
Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31(1): 51-72.
[16]
Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol 2015; 25(1): 11-7.
[17]
Shen RN, Hornback NB, Shidnia H, Lu L, Montebello JF, Brahmi Z. A comparison of lung metastases and natural killer cell activity in daily fractions and weekly fractions of radiation therapy on murine B16a melanoma. Radiat Res 1988; 114(2): 354-60.
[18]
Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8 + T cells: Changing strategies for cancer treatment. Blood 2009; 114(3): 589-95.
[19]
Smilowitz HM, Micca PL, Sasso D, et al. Increasing radiation dose improves immunotherapy outcome and prolongation of tumor dormancy in a subgroup of mice treated for advanced intracerebral melanoma. Cancer Immunol Immunother 2016; 65(2): 127-39.
[20]
Mackley HB, Liu J, Zhu J. Improved infield response rates and overall survival in patients with metastatic melanoma receiving higher biological equivalent doses of radiation with ipilimumab. J Radiat Oncol 2017; 6(2): 215-23.
[21]
Marconi R, Strolin S, Bossi G, Strigari L. A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger? PLoS One 2017; 12(2) e0171559
[22]
Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991; 20(3): 429-32.
[23]
Rofstad EK. Fractionation sensitivity (alpha/beta ratio) of human melanoma xenografts. Radiother Oncol 1994; 33(2): 133-8.
[24]
Zavgorodni S. The impact of inter-fraction dose variations on biological equivalent dose (BED): The concept of equivalent constant dose. Phys Med Biol 2004; 49(23): 5333-45.
[25]
Overgaard J, Overgaard M, Hansen PV, von der Maase H. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 1986; 5(3): 183-92.
[26]
Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012; 83(4): 1306-10.
[27]
Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15(17): 5379-88.
[28]
Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy. Lancet Oncol 2015; 16(13): e498-509.
[29]
Filippi AR, Fava P, Badellino S, Astrua C, Ricardi U, Quaglino P. Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiother Oncol 2016; 120(1): 1-12.
[30]
Qin R, Olson A, Singh B, et al. Safety and efficacy of radiation therapy in advanced melanoma patients treated with Ipilimumab. Int J Radiat Oncol 2016; 96(1): 72-7.
[31]
Ang KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994; 30(4): 795-8.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [78 - 85]
Pages: 8
DOI: 10.2174/2542584601666180326111906
Price: $65

Article Metrics

PDF: 24
HTML: 3